Commercial-stage biotechnology company Heron Therapeutics Inc (Nasdaq: HRTX) announced on Tuesday the appointment of Brett Fleshman as chief business officer.

Fleshman brings 25 years of experience in corporate and business development, commercial strategy and marketing of pharmaceuticals, biologics and surgical devices.

Previously, Fleshman was managing director at NovaQuest Capital Management, with responsibility for deal sourcing, structuring nondilutive investments, negotiations, diligence and post-close investment management. Prior to that he served as vice president of Strategy and Corporate Development for Veloxis Pharmaceuticals and held senior commercial and business development roles at Cornerstone Therapeutics. Earlier in his career Fleshman served in senior marketing roles at Ther-Rx Corporation and Genzyme Biosurgery, now Sanofi Genzyme.